NXEN (Nexien BioPharma) Operating Margin %: 0.00% (As of Mar. 2025)


What is Nexien BioPharma Operating Margin %?

Nexien BioPharma NXEN Operating Margin % is 0.00% as of Mar. 2025.

Operating Margin % is calculated as Operating Income divided by its Revenue. Nexien BioPharma's Operating Income for the three months ended in Mar. 2025 was $-0.01 Mil. Nexien BioPharma's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Nexien BioPharma's Operating Margin % for the quarter that ended in Mar. 2025 was 0.00%.

The historical rank and industry rank for Nexien BioPharma's Operating Margin % or its related term are showing as below:


NXEN's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.58
* Ranked among companies with meaningful Operating Margin % only.

Nexien BioPharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Nexien BioPharma's Operating Income for the three months ended in Mar. 2025 was $-0.01 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.12 Mil.


Nexien BioPharma  (OTCPK:NXEN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nexien BioPharma Operating Margin % Related Terms


Nexien BioPharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Nexien BioPharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma Operating Margin % Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Operating Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nexien BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NXEN vs FLHLF, ZTS, UTHR: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexien BioPharma Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's Operating Margin % falls into.



Nexien BioPharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nexien BioPharma's Operating Margin % for the fiscal year that ended in Jun. 2024 is calculated as

Operating Margin %=Operating Income (A: Jun. 2024 ) / Revenue (A: Jun. 2024 )
=-0.156 / 0
= %

Nexien BioPharma's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=-0.014 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Nexien BioPharma (NXEN) has a Operating Margin % of 0.00% as of Mar. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Nexien BioPharma and its competitors.
Is Nexien BioPharma's Operating Margin % too high?
Nexien BioPharma's current Operating Margin % is 0.00%.
How does Nexien BioPharma's Operating Margin % compare to FLHLF and ZTS?
Nexien BioPharma's Operating Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Operating Margin % is 7.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Nexien BioPharma and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexien BioPharma's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexien BioPharma stock overvalued right now?
Nexien BioPharma (NXEN) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Nexien BioPharma (NXEN), the current Operating Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexien BioPharma Business Description

Address 4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is engaged in pre-clinical and drug development activities, by U.S. Food and Drug Administration (FDA) protocols, for certain pharmaceutical formulations that include cannabinoids. The company is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders, and medical conditions.